ArticleHealth science reports2025
Exploring the Association Between Human Blood Metabolites and Autism Spectrum Disorder Risk: A Bidirectional Mendelian Randomization Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Autism spectrum disorder (ASD) is a complex neurodevelopmental condition with a poorly understood etiology. Recent studies have suggested that metabolic dysregulation might be linked to the development of ASD; however, causal relationships remain unclear. This study aimed to investigate the causal association between these factors using two-sample Mendelian randomization (TSMR). Methods: We conducted a TSMR analysis to assess the relationship between blood metabolites and ASD using summarized GWAS data. The metabolite dataset from the Canadian Longitudinal Study of Aging included 1091 metabolites and 309 ratios from 7824 European individuals. The ASD data from the Psychiatric Genomics Consortium comprised 18,381 ASD cases and 27,969 controls. Blood metabolites were set as exposures with ASD as the outcome. We primarily used the inverse-variance weighted method, supplemented by MR-Egger, weighted median, simple mode, and weighted mode methods. We also conducted sensitivity analyses to confirm robustness. Replication, confounding, and reserve analyses were performed to verify causation. Additionally, metabolic pathway and network pharmacology analyses were conducted to explore potential mechanisms. Results: We identified 55 known metabolites including 13 metabolite ratios and 10 unknown blood metabolites associated with ASD. Additionally, our analysis identified 13 potential metabolic pathways, among which tryptophan metabolism was the most notable ( Conclusions: Our findings indicate that the dodecenedioate, methionine sulfone, cysteine to alanine ratio and proline to glutamate ratio have an impact on ASD. These results enhance our understanding of the metabolic pathways involved in ASD and could lead to new avenues for intervention and prevention. Further research is needed to explore the mechanisms underlying these associations and confirm these findings in different populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.